TG Therapeutics (TGTX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
11 Jun, 2026Opening remarks and agenda
The meeting was formally called to order and directors, auditors, and legal counsel were introduced.
The agenda included voting on three items as described in the proxy statement.
Board and executive committee updates
Directors nominated for election included Laurence N. Charney, Yann Echelard, Kenneth Hoberman, Daniel Hume, Dr. Sagar Lonial, and Michael S. Weiss, to serve until the 2027 annual meeting or until successors are elected.
Shareholder proposals
Three items were presented for shareholder voting: election of directors, ratification of KPMG LLP as auditors for 2026, and an advisory vote on executive compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from TG Therapeutics
- Sub-Q launch and label updates aim to drive growth, expand market, and enhance patient experience.TGTX
Goldman Sachs 47th Annual Global Healthcare Conference 20269 Jun 2026 - SUB-Q BRIUMVI data signals major market expansion and strong competitive positioning.TGTX
Jefferies Global Healthcare Conference 20263 Jun 2026 - Q1 2026 revenue hit $205M, guidance raised, and liquidity boosted by a $750M loan.TGTX
Q1 202612 May 2026 - Annual meeting to elect directors, ratify auditor, and approve pay, with strong governance focus.TGTX
Proxy filing1 May 2026 - 2025 revenue soared 92% on BRIUMVI growth, with strong 2026 guidance and global expansion.TGTX
Q4 20259 Apr 2026 - Q2 BRIUMVI sales soared 350%+, driving raised guidance, profitability, and new capital moves.TGTX
Q2 20242 Feb 2026 - BRIUMVI's rapid adoption and pipeline expansion position it for CD20 market leadership.TGTX
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Briumvi drives MS market growth, with new patents, pipeline expansion, and a subQ version in development.TGTX
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Briumvi Q3 revenue up 230% year-over-year; full-year guidance raised to $300–$305M.TGTX
Q3 202417 Jan 2026